Zai Lab Reports Zoci Response and Six-Month PFS Rates in Phase 1L Trial

At the recommended Phase 3 dose of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated six-month progression-free survival rate of 81.9% (n=33) in first-line extensive-stage small cell lung cancer.